QQQ   431.85 (+0.18%)
AAPL   169.32 (-1.95%)
MSFT   416.93 (+0.80%)
META   501.56 (+0.27%)
GOOGL   154.34 (-0.34%)
AMZN   184.47 (+0.46%)
TSLA   157.93 (-2.20%)
NVDA   874.72 (+1.71%)
AMD   164.24 (+2.45%)
NIO   3.83 (-1.54%)
BABA   69.51 (-1.57%)
T   15.99 (-1.54%)
F   12.09 (-1.14%)
MU   120.96 (-0.34%)
GE   154.35 (+0.42%)
CGC   7.04 (+0.86%)
DIS   114.14 (+1.05%)
AMC   2.66 (+7.69%)
PFE   25.83 (-0.31%)
PYPL   63.84 (+0.52%)
XOM   118.83 (-0.71%)
QQQ   431.85 (+0.18%)
AAPL   169.32 (-1.95%)
MSFT   416.93 (+0.80%)
META   501.56 (+0.27%)
GOOGL   154.34 (-0.34%)
AMZN   184.47 (+0.46%)
TSLA   157.93 (-2.20%)
NVDA   874.72 (+1.71%)
AMD   164.24 (+2.45%)
NIO   3.83 (-1.54%)
BABA   69.51 (-1.57%)
T   15.99 (-1.54%)
F   12.09 (-1.14%)
MU   120.96 (-0.34%)
GE   154.35 (+0.42%)
CGC   7.04 (+0.86%)
DIS   114.14 (+1.05%)
AMC   2.66 (+7.69%)
PFE   25.83 (-0.31%)
PYPL   63.84 (+0.52%)
XOM   118.83 (-0.71%)
QQQ   431.85 (+0.18%)
AAPL   169.32 (-1.95%)
MSFT   416.93 (+0.80%)
META   501.56 (+0.27%)
GOOGL   154.34 (-0.34%)
AMZN   184.47 (+0.46%)
TSLA   157.93 (-2.20%)
NVDA   874.72 (+1.71%)
AMD   164.24 (+2.45%)
NIO   3.83 (-1.54%)
BABA   69.51 (-1.57%)
T   15.99 (-1.54%)
F   12.09 (-1.14%)
MU   120.96 (-0.34%)
GE   154.35 (+0.42%)
CGC   7.04 (+0.86%)
DIS   114.14 (+1.05%)
AMC   2.66 (+7.69%)
PFE   25.83 (-0.31%)
PYPL   63.84 (+0.52%)
XOM   118.83 (-0.71%)
QQQ   431.85 (+0.18%)
AAPL   169.32 (-1.95%)
MSFT   416.93 (+0.80%)
META   501.56 (+0.27%)
GOOGL   154.34 (-0.34%)
AMZN   184.47 (+0.46%)
TSLA   157.93 (-2.20%)
NVDA   874.72 (+1.71%)
AMD   164.24 (+2.45%)
NIO   3.83 (-1.54%)
BABA   69.51 (-1.57%)
T   15.99 (-1.54%)
F   12.09 (-1.14%)
MU   120.96 (-0.34%)
GE   154.35 (+0.42%)
CGC   7.04 (+0.86%)
DIS   114.14 (+1.05%)
AMC   2.66 (+7.69%)
PFE   25.83 (-0.31%)
PYPL   63.84 (+0.52%)
XOM   118.83 (-0.71%)
NASDAQ:JAGX

Jaguar Health (JAGX) Stock Price, News & Analysis

$0.17
+0.05 (+44.28%)
(As of 11:28 AM ET)
Today's Range
$0.14
$0.26
50-Day Range
$0.06
$0.14
52-Week Range
$0.05
$1.22
Volume
439.74 million shs
Average Volume
46.99 million shs
Market Capitalization
$47.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
JAGX stock logo

About Jaguar Health Stock (NASDAQ:JAGX)

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.

JAGX Stock Price History

JAGX Stock News Headlines

Why Is Jaguar Health (JAGX) Stock Up 44% Today?
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
What Wall Street expects from Jaguar Health's earnings
Jaguar Health, Inc.
Capricor Therapeutics, Inc. (4LN2.F)
Jaguar Health Inc
Jaguar Health, Inc. (JAGX)
See More Headlines
Receive JAGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/17/2021
Today
4/16/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:JAGX
Fax
N/A
Employees
60
Year Founded
N/A

Profitability

Net Income
$-41,300,000.00
Net Margins
-423.11%
Pretax Margin
-429.27%

Debt

Sales & Book Value

Annual Sales
$9.76 million
Book Value
$0.07 per share

Miscellaneous

Free Float
276,161,000
Market Cap
$32.81 million
Optionable
No Data
Beta
1.35
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Ms. Lisa A. Conte (Age 65)
    Founder, CEO, President & Director
    Comp: $771.4k
  • Dr. Pravin R. Chaturvedi Ph.D. (Age 61)
    Chief Scientific Officer & Chair of Scientific Advisory Board
    Comp: $539.04k
  • Mr. Jonathan S. Wolin CPA (Age 61)
    J.D., M.B.A., Chief of Staff, Chief Compliance Officer & General Counsel
    Comp: $520.29k
  • Mr. Ian H. Wendt M.B.A. (Age 56)
    Chief Commercial Officer
    Comp: $441.31k
  • Dr. Steven R. King Ph.D. (Age 66)
    Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Secretary
    Comp: $477.66k
  • Ms. Carol R. Lizak M.B.A. (Age 60)
    Chief Financial Officer
  • Mr. Peter Hodge
    Senior Director of Investor Relations, Business Development & Special Events
  • Dr. Karen J. Brunke Ph.D. (Age 71)
    Executive VP of Corporate & Business Development
  • Mr. David Sesin
    Chief Manufacturing Officer

JAGX Stock Analysis - Frequently Asked Questions

How have JAGX shares performed in 2024?

Jaguar Health's stock was trading at $0.1514 at the beginning of the year. Since then, JAGX stock has decreased by 0.2% and is now trading at $0.1511.
View the best growth stocks for 2024 here
.

Are investors shorting Jaguar Health?

Jaguar Health saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 19,710,000 shares, an increase of 164.9% from the March 15th total of 7,440,000 shares. Based on an average daily trading volume, of 40,390,000 shares, the short-interest ratio is presently 0.5 days.
View Jaguar Health's Short Interest
.

When is Jaguar Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our JAGX earnings forecast
.

How were Jaguar Health's earnings last quarter?

Jaguar Health, Inc. (NASDAQ:JAGX) announced its quarterly earnings data on Wednesday, November, 17th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by $0.09. The biotechnology company earned $0.63 million during the quarter. Jaguar Health had a negative net margin of 423.11% and a negative trailing twelve-month return on equity of 837.11%. During the same period last year, the firm posted ($0.63) earnings per share.

When did Jaguar Health's stock split?

Jaguar Health's stock reverse split on the morning of Wednesday, September 8th 2021. The 1-3 reverse split was announced on Wednesday, September 8th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 8th 2021. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

What other stocks do shareholders of Jaguar Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), Trevena (TRVN), Vaxart (VXRT), Purple Biotech (KTOV), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Biopharmx (BPMX), Cara Therapeutics (CARA) and Conatus Pharmaceuticals (CNAT).

When did Jaguar Health IPO?

Jaguar Health (JAGX) raised $22 million in an initial public offering (IPO) on Wednesday, May 13th 2015. The company issued 3,200,000 shares at $7.00 per share. Aegis Capital Corp acted as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

How do I buy shares of Jaguar Health?

Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:JAGX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners